Daniel Siegwart is the founder of ReCode Therapeutics. ReCode Therapeutics has raised $570M in total funding. Latest round: Series B. Based in Menlo Park, CA.
Daniel J. Siegwart is a co-founder of ReCode Therapeutics, a clinical-stage genetic medicines company focused on mRNA and gene correction therapeutics for rare genetic diseases. He is affiliated with UT Southwestern Medical Center and played a key role in developing the company's Selective Organ Targeting (SORT) platform.
Full founder directory · Investor directory · Company funding database · Fundraising library